The American Journal of Managed Care

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

INCA033989 targets CALR mutations, showing efficacy in engineered cell lines and mouse models of MPNs, without affecting other cells. CALR mutations are significant in JAK2V617F-negative essential ...

CAR T cell therapy targets key mutation driving rare blood cancers

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...
Business Wire

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators ...
Cure Today

FDA Grants Breakthrough Designation to INCA-33989 in Essential Thrombocythemia

INCA033989 targets mutCALR in ET patients with Type 1 CALR mutations, showing promise in early trials with rapid, durable hematological responses and a favorable safety profile. CALR mutations are ...
Nasdaq

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...